Large pharmaceutical companies face criticism on several fronts: they use legal tactics to block cheaper generic drugs, spend heavily on political influence, have fueled public health crises like the opioid epidemic, and operate within a pricing system so opaque that even regulators struggle to follow the money. Some of these criticisms are straightforward and well-documented. Others involve a tangled web of middlemen and incentives that make the full picture harder to see than most people realize.
Keeping Generic Drugs Off the Market
When a pharmaceutical company develops a new drug, it receives patent protection that typically lasts 20 years. That monopoly period is meant to let the company recoup its investment before competitors can sell cheaper generic versions. The problem is what happens as that expiration date approaches.
Companies routinely use a strategy called “product hopping,” where they make minor changes to an existing drug, such as switching from a twice-daily pill to a once-daily version, patent the new formulation, and then aggressively market doctors and patients to switch. In some cases, the company pulls the original version from the market entirely before its patent expires, forcing everyone onto the newer, still-protected version. Actavis tried this with Namenda, a $1.5 billion Alzheimer’s drug, attempting to replace its older formulation with a “new and improved” once-daily version patented until 2029. These aren’t medical breakthroughs. They’re legal maneuvers designed to restart the exclusivity clock.
This matters globally, too. International trade rules require most countries to honor 20-year patent protections on medicines, delaying the entry of lower-cost generics. Wealthier nations have pushed for even stricter intellectual property rules in trade agreements, and many low-income countries lack the manufacturing capacity to produce generics even when they’re legally permitted to. The result is that essential medicines remain unaffordable in the places that need them most.
The Rebate System That Inflates Prices
Drug pricing in the U.S. isn’t just a story about pharmaceutical companies setting high prices. It’s also about pharmacy benefit managers, or PBMs, the middlemen who negotiate drug costs on behalf of insurance plans. The three largest PBMs (owned by CVS Health, Cigna, and UnitedHealth Group) control the vast majority of the market, and the way they operate creates perverse incentives.
Here’s how it works: drug manufacturers pay rebates to PBMs in exchange for “preferred” placement on an insurance plan’s list of covered drugs. If your medication lands on the preferred tier, you pay a lower copay and the manufacturer sells more prescriptions. If it doesn’t, patients pay more and prescriptions drop. This gives PBMs enormous leverage, but the system rewards higher list prices rather than lower ones, because rebates are typically calculated as a percentage of the list price. A bigger sticker price means a bigger rebate, which means more money for the PBM to keep.
PBMs are not required to publicly disclose how much of these rebates they retain versus how much they pass on to insurers or patients. The Federal Trade Commission has taken action against the three major PBMs, accusing them of creating a “perverse drug rebate system” that artificially inflates the cost of insulin. So while pharmaceutical companies set the initial price, the rebate system gives them a financial reason to set it high, and the lack of transparency makes it nearly impossible for patients to understand why their prescriptions cost what they do.
Research That Tilts Toward Positive Results
Pharmaceutical companies fund the majority of clinical trials for their own products, and that funding comes with a measurable bias. A Cochrane review analyzing over 2,900 studies found that industry-sponsored trials were 27% more likely to report favorable results than independently funded research. Among non-industry studies, about 502 out of every 1,000 reported positive efficacy findings. For industry-sponsored studies, that number jumped to 638 per 1,000.
This doesn’t necessarily mean companies are fabricating data. The bias can show up in subtler ways: choosing comparisons that make a drug look better, designing trials around endpoints most likely to show benefit, or selectively emphasizing certain outcomes in published papers. The effect is that the medical literature, which doctors rely on to make prescribing decisions, is systematically skewed toward making drugs look more effective than independent evidence would suggest.
Compounding this problem, most clinical trial results never get reported publicly on time. A study published in the New England Journal of Medicine found that only 13.4% of trials reported results within the legally required 12-month window after completion. Even with no time limit, only 38.3% had reported results at all during the study period. That means the majority of trial data, including negative or inconclusive findings, sits unreported while doctors and patients make decisions based on incomplete information.
Political Spending and Lobbying Power
The pharmaceutical industry is one of the largest lobbying forces in U.S. politics. PhRMA, the main trade group for drug manufacturers, spent $37.9 million on lobbying in 2025 alone, up from $31 million the year before. That made it the third-highest lobbying spender across all industries in the country.
This spending buys access to lawmakers who shape drug pricing policy, patent law, and regulatory requirements. It’s one reason why proposals to let Medicare negotiate drug prices took decades to gain traction, and why the negotiations that finally passed in 2022 were limited to a small number of drugs. The industry’s political influence doesn’t just protect profits. It shapes the rules of the system itself.
The Opioid Crisis as a Case Study
The opioid epidemic is the most concrete example of pharmaceutical industry harm. Manufacturers like Purdue Pharma aggressively marketed opioid painkillers while downplaying their addictive potential, and distributors shipped massive quantities of pills to communities far too small to have legitimate need for them. The crisis has killed hundreds of thousands of Americans.
The financial reckoning has been significant but slow. Janssen Pharmaceuticals agreed to pay up to $5 billion over nine years. The three largest drug distributors, McKesson, Cardinal Health, and AmerisourceBergen (now Cencora), agreed to settlements totaling up to $21 billion over 18 years. These settlements fund addiction treatment and prevention programs, but they’re paid out over such long timelines that the companies absorb the cost gradually rather than facing the kind of immediate financial consequences that might deter future behavior.
Where the Money Actually Goes
One common defense of high drug prices is that they fund research and development. The numbers tell a more nuanced story. Large pharmaceutical companies spend an average of about 18.4% of their revenue on R&D, a figure that has remained relatively stable over the past decade even as sales have grown. Between 2008 and 2019, sales at major companies grew from $380 billion to $418 billion, while R&D spending increased 27.9%. That’s real investment, but R&D intensity (the share of revenue going to research) barely budged, ranging from 16.6% to 19.3%.
Meanwhile, total U.S. pharmaceutical spending hit $805.9 billion in 2024, a 10.2% increase over the previous year. Most of that growth came from increased utilization (people filling more prescriptions) and new drug launches, not from price hikes on existing drugs. That distinction matters: it means the system’s cost problem is partly about volume and partly about the price of new drugs entering the market at high launch prices, not just annual price increases on older medications.
The critique isn’t that pharmaceutical companies do no good. They develop drugs that save lives. The critique is that the system they operate within, and actively shape through lobbying, patent manipulation, and opaque pricing structures, consistently prioritizes profit extraction over patient access. The problems aren’t one company’s bad behavior. They’re structural, built into the incentives of how drugs are patented, priced, distributed, and sold.